Sangeeta N. Bhatia Sells 621 Shares of Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) Stock

Vertex Pharmaceuticals Incorporated (NASDAQ:VRTXGet Rating) Director Sangeeta N. Bhatia sold 621 shares of the business’s stock in a transaction that occurred on Friday, July 29th. The shares were sold at an average price of $278.77, for a total value of $173,116.17. Following the completion of the sale, the director now directly owns 5,282 shares of the company’s stock, valued at approximately $1,472,463.14. The sale was disclosed in a legal filing with the SEC, which is accessible through this link.

Vertex Pharmaceuticals Stock Performance

Shares of NASDAQ VRTX opened at $275.03 on Thursday. The business has a fifty day simple moving average of $277.11 and a 200 day simple moving average of $260.16. The company has a current ratio of 4.75, a quick ratio of 4.60 and a debt-to-equity ratio of 0.05. The firm has a market capitalization of $70.34 billion, a price-to-earnings ratio of 28.95, a PEG ratio of 2.02 and a beta of 0.45. Vertex Pharmaceuticals Incorporated has a one year low of $176.36 and a one year high of $296.84.

Vertex Pharmaceuticals (NASDAQ:VRTXGet Rating) last issued its earnings results on Thursday, May 5th. The pharmaceutical company reported $3.16 EPS for the quarter, missing analysts’ consensus estimates of $3.17 by ($0.01). The firm had revenue of $2.10 billion during the quarter, compared to analyst estimates of $2.07 billion. Vertex Pharmaceuticals had a net margin of 30.84% and a return on equity of 32.24%. The business’s revenue for the quarter was up 21.6% compared to the same quarter last year. During the same quarter in the previous year, the company posted $2.54 earnings per share. Sell-side analysts expect that Vertex Pharmaceuticals Incorporated will post 12.41 EPS for the current year.

Analyst Upgrades and Downgrades

VRTX has been the subject of several recent research reports. Piper Sandler boosted their price target on Vertex Pharmaceuticals from $242.00 to $256.00 and gave the company a “neutral” rating in a research note on Tuesday, July 26th. Cowen boosted their target price on Vertex Pharmaceuticals from $305.00 to $310.00 in a report on Monday, June 13th. Argus boosted their target price on Vertex Pharmaceuticals from $275.00 to $280.00 and gave the stock a “buy” rating in a report on Monday, June 13th. UBS Group boosted their target price on Vertex Pharmaceuticals from $258.00 to $325.00 in a report on Wednesday, April 13th. Finally, Wells Fargo & Company boosted their target price on Vertex Pharmaceuticals from $300.00 to $305.00 in a report on Friday, May 6th. Six investment analysts have rated the stock with a hold rating, ten have assigned a buy rating and one has given a strong buy rating to the stock. Based on data from MarketBeat.com, Vertex Pharmaceuticals presently has a consensus rating of “Moderate Buy” and a consensus price target of $287.68.

Institutional Trading of Vertex Pharmaceuticals

Large investors have recently bought and sold shares of the stock. JJJ Advisors Inc. grew its position in Vertex Pharmaceuticals by 101.5% in the fourth quarter. JJJ Advisors Inc. now owns 133 shares of the pharmaceutical company’s stock valued at $29,000 after acquiring an additional 67 shares during the period. Trustcore Financial Services LLC grew its holdings in shares of Vertex Pharmaceuticals by 53.8% during the fourth quarter. Trustcore Financial Services LLC now owns 143 shares of the pharmaceutical company’s stock worth $31,000 after purchasing an additional 50 shares during the last quarter. TFC Financial Management grew its holdings in shares of Vertex Pharmaceuticals by 58.0% during the second quarter. TFC Financial Management now owns 109 shares of the pharmaceutical company’s stock worth $31,000 after purchasing an additional 40 shares during the last quarter. Crewe Advisors LLC bought a new stake in shares of Vertex Pharmaceuticals during the fourth quarter worth $32,000. Finally, Sittner & Nelson LLC grew its holdings in shares of Vertex Pharmaceuticals by 66.7% during the first quarter. Sittner & Nelson LLC now owns 125 shares of the pharmaceutical company’s stock worth $33,000 after purchasing an additional 50 shares during the last quarter. 89.84% of the stock is currently owned by institutional investors.

Vertex Pharmaceuticals Company Profile

(Get Rating)

Vertex Pharmaceuticals Incorporated, a biotechnology company, engages in developing and commercializing therapies for treating cystic fibrosis. The company markets SYMDEKO/SYMKEVI, ORKAMBI, and KALYDECO to treat patients with cystic fibrosis who have specific mutations in their cystic fibrosis transmembrane conductance regulator gene; and TRIKAFTA for the treatment of patients with CF 6 years of age or older who have at least one F508del mutation.

Recommended Stories

Insider Buying and Selling by Quarter for Vertex Pharmaceuticals (NASDAQ:VRTX)

Receive News & Ratings for Vertex Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Vertex Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.